ES2036737T3 - Procedimiento para la obtencion de mezclas farmaceuticas. - Google Patents

Procedimiento para la obtencion de mezclas farmaceuticas.

Info

Publication number
ES2036737T3
ES2036737T3 ES198989105917T ES89105917T ES2036737T3 ES 2036737 T3 ES2036737 T3 ES 2036737T3 ES 198989105917 T ES198989105917 T ES 198989105917T ES 89105917 T ES89105917 T ES 89105917T ES 2036737 T3 ES2036737 T3 ES 2036737T3
Authority
ES
Spain
Prior art keywords
procedure
pharmaceutical mixtures
obtaining pharmaceutical
obtaining
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198989105917T
Other languages
English (en)
Spanish (es)
Inventor
Roger Dr. Klimesch
Gerhard Bleckmann
Lothar Schlemmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Application granted granted Critical
Publication of ES2036737T3 publication Critical patent/ES2036737T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C45/00—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor
    • B29C45/0001—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor characterised by the choice of material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035—Medical or pharmaceutical agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Veterinary Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES198989105917T 1988-04-15 1989-04-05 Procedimiento para la obtencion de mezclas farmaceuticas. Expired - Lifetime ES2036737T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3812567A DE3812567A1 (de) 1988-04-15 1988-04-15 Verfahren zur herstellung pharmazeutischer mischungen

Publications (1)

Publication Number Publication Date
ES2036737T3 true ES2036737T3 (es) 1993-06-01

Family

ID=6352067

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198989105917T Expired - Lifetime ES2036737T3 (es) 1988-04-15 1989-04-05 Procedimiento para la obtencion de mezclas farmaceuticas.

Country Status (8)

Country Link
US (1) US4957681A (enExample)
EP (1) EP0337256B1 (enExample)
JP (1) JP2839544B2 (enExample)
AT (1) ATE82495T1 (enExample)
CA (1) CA1338929C (enExample)
DE (2) DE3812567A1 (enExample)
ES (1) ES2036737T3 (enExample)
GR (1) GR3007096T3 (enExample)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4031881C2 (de) * 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
WO1992018106A1 (fr) † 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
CA2117351C (en) * 1992-01-13 1998-03-03 Julian Belknap Lo Preparation of tablets of increased strength
JPH0656659A (ja) * 1992-06-10 1994-03-01 Natl Sci Council 直接打錠できる薬学組成物及びその錠剤の製造法
JP2616252B2 (ja) * 1992-10-16 1997-06-04 日本新薬株式会社 ワックスマトリックスの製法
IL110139A0 (en) * 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE19629753A1 (de) 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
HRP970485A2 (en) 1996-09-13 1998-08-31 Joerg Rosenberg Process for producing solid pharmaceutical forms
DE19710213A1 (de) * 1997-03-12 1998-09-17 Basf Ag Verfahren zur Herstellung von festen Kombinationsarzneiformen
DE19753298A1 (de) 1997-12-01 1999-06-02 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
JP2001526228A (ja) 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド作動薬／拮抗薬の併用
DE19812688A1 (de) 1998-03-23 1999-09-30 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
DE19840256A1 (de) 1998-09-03 2000-03-09 Basf Ag Verfahren zur Herstellung von beschichteten festen Dosierungsformen
DE19841244A1 (de) 1998-09-09 2000-03-16 Knoll Ag Verfahren und Vorrichtung zum Herstellen von Tabletten
DE19843904A1 (de) 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit polymerem Bindemittel
DE19847618A1 (de) 1998-10-15 2000-04-20 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
DE19901383A1 (de) 1999-01-15 2000-07-20 Knoll Ag Verfahren zur Herstellung unterschiedlicher fester Dosierungsformen
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
KR100889069B1 (ko) 1999-10-29 2009-03-17 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
DE19960494A1 (de) * 1999-12-15 2001-06-21 Knoll Ag Vorrichtung und Verfahren zum Herstellen von festen wirkstoffhaltigen Formen
EP1935421A1 (en) 2000-02-08 2008-06-25 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
HU229705B1 (en) 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
DE10017102A1 (de) 2000-04-06 2001-10-11 Basf Ag Verfahren zur Herstellung von festen Kreatin-Dosierungsformen und dadurch erhältliche Dosierungsformen
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
AU2738302A (en) 2000-10-30 2002-05-15 Euro Celtique Sa Controlled release hydrocodone formulations
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
ATE431738T1 (de) 2001-08-06 2009-06-15 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
DE10247037A1 (de) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
CN101480384A (zh) * 2002-12-17 2009-07-15 阿伯特有限及两合公司 包含非诺贝酸、其生理可接受的盐或衍生物的制剂
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US7423004B2 (en) * 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
EP1615625A4 (en) 2003-04-21 2010-12-15 Euro Celtique Sa SAFETY DOSING FORM WITH COEXTRUDED PARTICLES OF AN UNWANTED MEDIUM AND METHOD OF MANUFACTURING THEREOF
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8075872B2 (en) * 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
EP1663229B1 (en) 2003-09-25 2010-04-14 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
ES2600577T3 (es) * 2003-12-04 2017-02-09 Bend Research, Inc. Procedimiento de pulverización-solidificación que usa un extrusor para preparar composiciones en multipartículas de fármacos cristalinos
MXPA06005913A (es) * 2003-12-04 2006-06-27 Pfizer Prod Inc Formas de dosificacion de multiparticulas de azitromicina por procedimientos basados en liquidos.
CA2547597A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
KR100844628B1 (ko) * 2003-12-04 2008-07-07 화이자 프로덕츠 인크. 제약상 다입자의 제조 방법
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
EP1701702A1 (en) * 2003-12-04 2006-09-20 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
CA2548834C (en) * 2003-12-09 2009-08-11 Euro-Celtique S.A. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
US8883204B2 (en) 2003-12-09 2014-11-11 Purdue Pharma L.P. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
RS50817B (sr) * 2004-03-30 2010-08-31 Euro-Celtique S.A. Dozni oblik otporan na promene koji sadrži adsorbenti i sredstvo sa suprotnim dejstvom
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
EP1748762B1 (de) * 2004-05-28 2013-12-18 AbbVie Deutschland GmbH & Co KG Dosierungsform, erhältlich aus einer ein anorganisches pigment umfassenden pulvermischung
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
CA2916869A1 (en) 2004-06-12 2005-12-29 Jane C. Hirsh Abuse-deterrent drug formulations
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
CA2594373A1 (en) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
ATE476997T1 (de) * 2005-07-05 2010-08-15 Abbott Gmbh & Co Kg Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
WO2007017249A1 (en) * 2005-08-08 2007-02-15 Abbott Gmbh & Co. Kg Dosage forms with improved bioavailability
JP5538718B2 (ja) 2005-08-08 2014-07-02 アボット ゲーエムベーハー ウント コンパニー カーゲー 改善された生物学的利用能をもつイトラコナゾール組成物
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
EP1832281A1 (en) * 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
CA2669938C (en) * 2006-11-15 2016-01-05 Abbott Laboratories Solid pharmaceutical dosage formulations
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
EP2219622A1 (en) 2007-12-06 2010-08-25 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
CA2737400C (en) * 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
KR101738369B1 (ko) 2009-07-22 2017-05-22 그뤼넨탈 게엠베하 핫 멜트 압출된 제어 방출 투여형
WO2011032860A1 (de) * 2009-09-18 2011-03-24 Basf Se Verfahren zur herstellung von zubereitungen von in wasser schwerlöslichen substanzen
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
ES2606227T3 (es) 2010-02-03 2017-03-23 Grünenthal GmbH Preparación de una composición farmacéutica en polvo mediante una extrusora
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
BR112013005194A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo sal inorgânico
ME02874B (me) 2010-12-22 2018-04-20 Purdue Pharma Lp Obloženi dozni oblici sa kontrolisanim oslobađanjem otporni na zloupotrebu
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
BR112014001091A2 (pt) 2011-07-29 2017-02-14 Gruenenthal Gmbh comprimido resistente à adulteração que fornece liberação imediata do fármaco
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
EP2838512B1 (en) 2012-04-18 2018-08-22 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP2872516B1 (en) 2012-07-16 2017-08-30 Rhodes Technologies Process for improved opioid synthesis
KR101946104B1 (ko) 2012-07-16 2019-02-08 로드스 테크놀로지즈 개선된 오피오이드 합성을 위한 방법
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CA2919602C (en) 2013-08-02 2018-03-13 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3094633B1 (en) 2014-01-15 2018-03-14 Rhodes Technologies Process for improved oxymorphone synthesis
KR101868723B1 (ko) 2014-01-15 2018-06-18 로드스 테크놀로지즈 개선된 옥시코돈 합성을 위한 방법
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413123A1 (fr) * 1977-12-30 1979-07-27 Philagro Sa Procede d'encapsulation par polycondensation interfaciale
JPS562149A (en) * 1979-06-19 1981-01-10 Mitsubishi Petrochem Co Ltd Continuous manufacture of aqueous dispersion of olefin resin
US4353482A (en) * 1980-01-23 1982-10-12 Halliburton Company Additive metering control system
DE3612211A1 (de) * 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
US4722456A (en) * 1986-07-25 1988-02-02 Acrison, Inc. With accelerometer for detecting extraneous disturbances weigh feeder
IE873172L (en) * 1986-12-29 1988-06-29 Harvard College Continuous process for producing a comestible tablet

Also Published As

Publication number Publication date
ATE82495T1 (de) 1992-12-15
US4957681A (en) 1990-09-18
DE58902737D1 (de) 1992-12-24
EP0337256B1 (de) 1992-11-19
JPH01305955A (ja) 1989-12-11
JP2839544B2 (ja) 1998-12-16
GR3007096T3 (enExample) 1993-07-30
DE3812567A1 (de) 1989-10-26
EP0337256A2 (de) 1989-10-18
CA1338929C (en) 1997-02-25
EP0337256A3 (de) 1991-02-06

Similar Documents

Publication Publication Date Title
ES2036737T3 (es) Procedimiento para la obtencion de mezclas farmaceuticas.
FI830100L (fi) Nya 6-substituerade s-triazolo /3,4-a/ ftalazinderivat
ES491183A0 (es) Procedimiento para la preparacion de acidos 3-cefem-4-carbo-xilicos sustituidos en la posicion 7
ES538231A0 (es) Procedimiento para la preparacion de derivado de esfingosina.
MX22877A (es) Procedimiento para la preparacion de pirimidas, producto obtenido y composicion farmaceutica que lo incluye
DK173883D0 (da) Substituerede 8-phenylxanthiner
MX6618E (es) Procedimiento para la preparacion de derivados de azetidina
RO89235A (ro) Procedeu pentru prepararea unor derivati de tidozina
AU623805B2 (en) New use of anti-progestomimetic compounds
ES497530A0 (es) Procedimiento para la preparacion de derivados de 2,3-indo- lediona
MX6424A (es) Derivados de tripeptidos, procedimientos para la preparacion de derivados de tripeptidos y composiciones que los contienen.
ES491683A0 (es) Procedimiento para la preparacion de 1,3,7-trialquilxantinas
AR230447A1 (es) Procedimiento para la preparacion de nuevos derivados sustituidos de 3,7-diazabiciclo-3,3,1-nonano,y procedimiento para la preparacion de las sustancias iniciales para dicho procedimiento
ES2013216A4 (es) Proceso para la preparacion de n - fosfonometilglicina
IT8221801A0 (it) Derivati di 1, 2, 3,4-tetraidronaftalene, procedimentodi preparazione e relative composizioni farmaceutiche.
MX174317B (es) Procedimiento para la preparacion de 1-hidroximetilpirazoles
ES501213A0 (es) Procedimiento para la preparacion de derivados de 2,3,4,5- tetrahidro-1-benzoxepin-3,5-diona
MX15050A (es) Procedimiento para la preparacion de derivados de 1-arilsulfinil-2-pirrolidinona.
IT1241128B (it) Procedimento per la preparazione di derivati chinazolinici
MX155724A (es) Procedimiento para la preparacion de derivados de prolina
MX159632A (es) Procedimiento para la preparacion de derivados de pirimidina 2,4,6,triona
AR228166A1 (es) Procedimiento para la fabricacion de derivados de 5,6,7,7a-tetrahidro-4h-tieno(3,2-c)-fenilalquil-5-piridin-2-ona
ES2051916T3 (es) Procedimiento para la obtencion de formiltrimetilbiciclo(2.2.2)oct-7-enos isomeros.
ES534479A0 (es) Procedimiento para la preparacion de derivados de propan-2-ol
MX9101959A (es) Procedimiento para la preparacion de trioxano

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 337256

Country of ref document: ES